Gunzburg announced the completion of post-registration studies of "Sputnik V"

Director of the National Research Center for Epidemiology and Microbiology named after Gamaleya Alexander Gintsburg announced the completion of post-registration studies of the Russian vaccine against coronavirus Sputnik V. His words are reported by RIA Novosti.

Gunzburg clarified that at the moment, documents have been submitted for permanent registration of the drug. “They are now being considered,” he added. It is noted that “Sputnik V” was registered in Russia “on conditions”: after registration it was necessary to conduct a clinical study.

The development of the Gamaleya Center became the world’s first registered vaccine against COVID-19. Currently “Sputnik V” is registered in 69 countries, the total population of which is more than 3.7 billion people. The drug is manufactured by more than 20 companies in 14 countries around the world.

Currently, five vaccines are registered in Russia: Sputnik V, EpiVacCorona, KoviVak, Sputnik Light and EpiVacCorona-N. The head of Rospotrebnadzor Anna Popova said that domestic vaccines against coronavirus are very effective.

Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more

Leave a Reply